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Abstract
Hierarchical Bayesian models can be especially useful in precision medicine settings, where clinicians are inter-
ested in estimating the patient-level latent variables associated with an individual’s current health state and
its trajectory. Such models are often fit using batch Markov Chain Monte Carlo (MCMC). However, the slow
speed of batch MCMC computation makes it difficult to implement in clinical settings, where immediate latent
variable estimates are often desired in response to new patient data. In this report, we discuss how importance
sampling (IS) can instead be used to obtain fast, in-clinic estimates of patient-level latent variables. We apply
IS to the hierarchical model proposed in Coley et al. (2015) for predicting an individual’s underlying prostate
cancer state. We find that latent variable estimates via IS can typically be obtained in 1-10 seconds per person
and have high agreement with estimates coming from longer-running batch MCMC methods. Alternative options
for out-of-sample fitting and online updating are also discussed.
Introduction
Hierarchical Bayesian models provide a natural statistical framework for precision medicine – allowing estimation
of both patient-level latent variables associated with health status trajectory, as well as population-level causal
effects of endogenous covariates and exogenous interventions. The use of a Bayesian framework encourages the
inclusion of existing medical knowledge at each level. When such models are fit on a training dataset using
Markov Chain Monte Carlo (MCMC), latent variable estimates are immediately available for any patient in the
training dataset. For example, Coley et al. (2015) use a patient-level latent class to categorize patients in a
training dataset as having either indolent or aggressive prostate cancer.
A computational challenge arises though when new patients enter the clinic or when existing patients accrue
new measurements. Here, clinicians may wish to give patients fast, in-visit estimates of their latent variables and
associated health states. However, batch MCMC estimation approaches that require refitting the entire model
can take hours to complete. Additionally, if the model is refit on protected clinical data from multiple sites, then
MCMC may require communication between fire-walled servers as the algorithm iterates, further increasing the
computation cost.
Instead, sampling algorithms tailored for out-of-sample fitting can be used to get fast latent variable estimates
in response to new patient data, while naturally avoiding the issue of server communication. Such algorithms
can be based on conditional posteriors (Wu et al., 2015), Gibbs Sampling (GS), Importance Sampling (IS), or
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Rejection Sampling (RS) (Bishop et al., 2006). In this report, we specifically describe how IS can be used to
obtain latent variable estimates for out-of-sample data. We also discuss conceptual parallels between these four
types of approaches. We then apply IS to the prostate cancer model proposed by Coley et al. (2015) to get fast
latent variable estimates for new, simulated patients. In this case, the IS procedure typically takes approximately
1-10 seconds per patient. This approach can be combined with periodic refitting of the entire model via MCMC,
in order to update the posteriors for the population-level parameters (Lee and Chia, 2002).
This IS approach is related to online (or streaming) learning methods, which aim to continuously update
population-level parameters with a constant computational cost over time. We avoid a fully online approach here
though, due to additional challenges in online learning. Specifically, our use of IS can be viewed as a 1-step version
of a sequential importance sampler (SIS), also known as particle filter. Employing a standard particle filter to
update estimates of the population-level parameters would seem to be a natural extension. However, particle
filters are known to suffer from the problem of degeneracy, which makes it difficult to estimate posteriors for
“static” parameters that do not change as more data is acquired (Kantas et al. (2014), see section II of Andrieu
et al. (2005) for an intuitive explanation). This concern applies in our case, as our population-level parameters
are assumed to be static. Instead, we combine IS with periodic MCMC (Lee and Chia, 2002) to update the
posteriors for all parameters and latent variables at all levels. Note that this is not a fully online method, as the
computational cost of MCMC increases as more data is acquired.1
Online model fitting has also been explored in the literature on topic modeling for corpuses of texts. Text
corpuses are often too large to fit an entire model on at once, making online fitting a more feasible option. Hoffman
et al. (2010) propose a online variational Bayes approach for topic modeling. Canini et al. (2009) propose a particle
filter approach, in a context where the static parameters can be integrated out. However, in the setting of Canini
et al. (2009), even the best performing online methods were outperformed by batch (non-online) MCMC, and
generally did not improve in accuracy as more data was incorporated.
Our specific context within precision medicine (Coley et al., 2015) is different than that of topic modeling in
that, while the model is complex and contains several layers, the data can be fully stored in memory at once.
Thus, while the approach of combining IS with periodic MCMC is not fully online and not feasible for text
analysis, it is still a feasible option for the limited sample sizes in our application. Relative to variational Bayes
approaches, the formulas required to apply IS are simple to derive and can be easily ported to other applications
within precision medicine.
The remainder of this document is organized as follows. In Section 1, we give an overview of our motivating
data example of latent prostate cancer state estimation. In Section 2, we detail our approach for applying IS to
hierarchical models. We use an abbreviated notation that can be readily generalized to other precision medicine
settings. In Section 3, we conceptually compare our IS approach with RS, GS, and conditional posteriors (Wu
et al., 2015). However, with the exception of RS, we do not explore the performance of these alternate methods
here. In Section 4, we apply IS to simulated data, and compare the results to latent variable estimates obtained
from batch MCMC.
1 Clinical Application & Motivation in Prostate Cancer
Our application is based on the clinical framework of Coley et al. (2015), who develop a latent class model
to predict underlying prostate cancer state in men participating in an active surveillance program for low risk
1See Kantas et al. (2014) for a recent literature review of particle methods in the context of static parameters.
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disease. The latent cancer state is defined as being “indolent” or “aggressive”, corresponding to the Gleason score
(Gleason, 1977, 1992) that would be assigned if a patient’s entire prostate were to be removed and analyzed.
Gleason scores < 6 are classified as indolent, and Gleason scores ≥ 7 are classified as aggressive. This latent state
is known only for those patients who elect to undergo a prostatectomy while under active surveillance, resulting
in a partially latent class problem. For those patients who do not elect to have their prostates removed, the model
of Coley et al. (2015) is used to estimate posterior probabilities of latent class membership, or, in other words,
the risk of having an aggressive cancer with the potential to metastasize. Latent variable predictions can then
be used by clinicians and patients to make decisions about future treatment or biopsies. This prediction tool
addresses a pressing need in prostate cancer care as the most common treatments for prostate cancer have a high
risk of persistent side effects including erectile dysfunction and urinary incontinence, while prostate biopsies are
painful and pose a risk of infection (Chou et al., 2011a,b).
The hierarchical model of Coley et al. (2015) includes sub-models for longitudinal prostate specific antigen
(PSA) measurements and for longitudinal biopsy results. Both of these sub-models incorporate information about
the patient’s latent state. More specifically, log-transformed PSA measurements are modeled with a stratified
random effects model where the distribution of patient-level random effects depends on latent state. Biopsy
results are coded as binary outcomes denoting grade reclassification on a biopsy, that is, the biopsied tissue was
assigned a Gleason score of 7 or higher. The log-odds of reclassification is modeled with a linear predictor whose
value also depends on a patient’s latent state, reflecting the imperfect sensitivity and specificity of the biopsy
procedure. Each patient’s latent class is assumed constant over the surveillance period. As a patient continues
in active surveillance, additional PSA and biopsy measurements are accrued and the accuracy of latent class
predictions improves. Sub-models are also included for informative observation processes associated with biopsies
and prostatectomies.
In our context, the patient-level latent variables refer to the latent classes and the random effects used in the
sub-model for PSA. The population-level parameters refer to the coefficients in each sub-model and the variance
parameters for the patient-level variables. See Coley et al. (2015) for a full model description.
2 IS Algorithm for Fast Estimates from New Data
In this section we detail an IS algorithm that enables rapid estimates of patient-level variables, such as latent
classes. This method is meant to be applied to out-of-sample data after MCMC has been applied to get a
posterior sample based on current training data. We present the algorithm in a simple, abbreviated notation that
is applicable in many clinical settings.
Let the joint posterior based on training data from n patients be denoted as
p(θ, b1:n|y1:n) ∝
n∏
i=1
[f(yi|bi, θ)g(bi|θ)]pi(θ) (1)
where yi is the vector of clinical measurements (here, PSA and biopsy measurements) for patient i, y1:n is the list
of measurements for the first n patients, bi is a vector of latent variables (here, latent class and random effects)
for patient i, b1:n is a list of latent variables for the first n patients, θ contains the population-level parameters,
pi is the prior for θ, and f and g are multivariate probability distributions chosen based on the application and
context. Estimation of bi is of primary interest in this report.
Let Jn = {θ(j), b(j)1:n}Jj=1 be a set of J draws from the posterior distribution in Eq 1 obtained via methods
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such as MCMC.
2.1 Core IS Algorithm
After posterior samples from the joint model (Jn) are obtained for current data, importance sampling to update
these estimates given new data requires three steps: (1) generating proposal values for the latent variables to be
estimated or updated, (2) calculating weights for proposed values, and (3) weighting proposed values to estimate
an updated posterior. We first illustrate how this process can be used to quickly estimate latent variables for a
new patient and then show how similar calculations can be done to incorporate newly measured data on existing
patients in real-time.
For a new patient (indexed by i = n+ 1), prediction of latent variables requires calculating expectations with
respect to the posterior distribution based on all n + 1 patients (i.e. p(θ, b1:(n+1)|y1:(n+1))). While we cannot
immediately draw from this distribution, we can evaluate a function that is proportional to its density (based on
Eq 1). We can also use the posterior distribution based on the first n patients as a proposal distribution (denoted
by q) from which to generate candidate values of (θ, b1:(n+1)). Let
q(θ, b1:(n+1)) := g(bn+1|θ)p(θ, b1:n|y1:n) (2)
Practically, this proposal step is achieved by conditioning on each θ(j) inJn and then drawing b
(j)
n+1 from the
distribution g(b
(j)
n+1|θ(j)). This results in the augmented setJn+1 := {θ(j), b(j)1:(n+1)}Jj=1. The importance weights
w(j) are then proportional to
w(j) ∝
p(θ(j), b
(j)
1:(n+1)|y1:(n+1))
q(θ(j), b
(j)
1:(n+1))
∝
∏n+1
i=1 [f(yi|b(j)i , θ(j))g(b(j)i |θ(j))]pi(θ(j))
g(b
(j)
n+1|θ(j))
∏n
i=1[f(yi|b(j)i , θ(j))g(bi|θ(j))]pi(θ(j))
= f(yn+1|b(j)n+1, θ(j)) (3)
The final weights w(j) are standardized to sum to 1. The new posterior for (θ, b1:(n+1)) can then be represented
as the mixture distribution satisfying P (θ = θ(j), b1:(n+1) = b
(j)
1:(n+1)) = w
(j). Posterior means for b(n+1) can be
calculated as
∑J
j=1 w
(j)b
(j)
(n+1).
The approach is similar when we wish to incorporate new measurement data for a patient k who’s previous data
has already informed the posterior sampleJn (i.e., k ≤ n). The setJn already contains proposals {b(j)k }Jj=1 for
patient k’s latent variable values. Thus, we can use draws fromJn as our proposal distribution q(θ(j), b
(j)
1:n). Our
goal then is to re-weight this set of proposals based on new data. Let y∗1:n refer to the data set after incorporating
new data on patient k, such that y∗i = yi if and only if k 6= i. The importance weights in Equation 3 then simplify
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to
w(j) ∝ p(θ
(j), b
(j)
1:n|y∗1:n)
q(θ(j), b
(j)
1:n)
∝
∏n
i=1[f(y
∗
i |b(j)i , θ(j))g(b(j)i |θ(j))]pi(θ(j))∏n
i=1[f(yi|b(j)i , θ(j))g(b(j)i |θ(j))]pi(θ(j))
=
f(y∗k|b(j)k , θ(j))
f(yk|b(j)k , θ(j))
(4)
If the repeated measures for each patient are independent conditional on bi, as is the case in the proposed model
from Coley et al. (2015), then the ratio in Eq 4 reduces to the likelihood of only the new data conditional on b
(j)
k
and θ(j).
2.2 Efficient Implementation
For implementation in clinical practice, proposals for new patients can be generated prior to actually observing
new data, so that only weight calculation and re-weighting of the proposal distribution needs to be done in
real-time.
By random chance, some new patients may have data such that very few of the pre-generated, proposed latent
variables values receive high weights. This will reduce the effective sample size of the posterior
(
1/
∑J
j=1
[(
w(j)
)2])
,
which in turn increases the Monte Carlo error of the posterior mean estimates.2 However, we can use the effective
sample size to flag patients who might have high error. When this effective sample size drops below a given
threshold (e.g. 1000), we can repeat our procedure with a larger set of pre-generated proposals (J). If limited
computing is available for MCMC, we can also approximate a larger set of proposals from Eq 2 by drawing
multiple bn+1 values for each θ
(j), rather than drawing just one.
3 Comparison to Alternative Algorithms for Fast Estimates from
New Data
In this section we outline some of the conceptual connections between our IS approach and out-of-sample fitting
approaches based on Rejection Sampling (RS), Gibbs Sampling, and conditional posteriors (Wu et al., 2015).
Most directly related to our IS approach, RS can also be applied using the unstandardized weights in Eq 3.
While RS allows for fewer particles to be stored in memory, we found IS to be more computationally efficient in
our scenario (see Section 4.1).
Out-of-sample estimation can also be done using Gibbs Sampling to update only the parameters associated
with new patient data (i.e., bn+1). One simple implementation is to run separate MCMC chains, each initialized
on a different element of Jn. Another approximate implementation that combines these chains is to treat
the set {θ(j)n }Jj=1 as fixed and to create a proxy categorical parameter z according to the following hierarchical
distribution:
2The effective sample size is also known as the effective number of particles.
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p ∼ Dirichlet(α = 1J)
z ∼ Categorical(p)
bn+1 ∼ g(θ(z))
yn+1 ∼ f(bn+1, θ(z))
where p is a J-length vector of probabilities, 1J is a J-length vector of ones, and z is a scalar such that P (z =
j) = pj for j = 1, 2, ...J . The above model can then be fit with traditional Gibbs Sampling, and the resulting
posterior estimates for p are analogous to the weights in Eq 3.
Finally, our IS approach functions similarly to the out-of-sample estimation approach of Wu et al. (2015).
Their approach can be generalized to estimate the updated posterior probability that P (bn+1 = x|y1:(n+1)) using
the estimator Pˆ (bn+1 = x|y1:(n+1)) :=
(
1
J
)∑J
j=1
{
f(yn+1|bn+1=x,θ(j))g(x|θ(j))´
f(yn+1|bn+1=x′,θ(j))g(x′|θ(j))dx′
}
. This approach is especially
practical when the patient-specific variables bn+1 are discrete, and the integral in the denominator can be replaced
with a summation. For cases with both continuous and discrete patient-specific variables, the approach can be
combined with a proposal generation method based on Eq 2. We do not explore the performance of this approach,
or of the above Gibbs Sampling approach, in this report.
4 Application
We applied the proposed IS approach to simulated data based on the Johns Hopkins Active Surveillance (JHAS)
cohort. 1,298 men with very low or low risk prostate cancer diagnoses were enrolled in JHAS from January 1995
to June 2014. Results of all PSA tests and biopsies performed prior to enrollment and during active surveillance
were collected. Patients were followed until grade reclassification, elective treatment, or loss to follow-up. Patients
still active in the program were administratively censored at the time of data collection for this analysis (October
2014). The Gleason score determination based on pathologic analysis of the entire prostate specimen was also
recored for patients who underwent prostatectomy. Details on the dataset are available in Coley et al. (2015).
Out simulated dataset consisted of 1,000 patients. The model proposed in Coley et al. (2015) was used as
the data generating model, with parameter values set equal to their corresponding posterior mean estimates from
fitting the model to the JHAS data. Covariates to the model (age and date of diagnosis) were each generated
from a normal distribution with mean and variance equal to that observed in JHAS patients. See Coley et al.
(2015) for more details on model specification and covariates.
Using this data as our initial sample (y1:n), we generate 500,000 draws (Jn) from the posterior for the
population-level and patient-level variables (see Eq 1). Averaging over Jn, we estimate the risk of having
aggressive cancer for each patient who’s latent class is unknown. The task of generating Jn was run across 400
parallel jobs on a x86-based linux cluster, with as many as 200 jobs allowed to run simultaneously. The total
elapsed computation time was 33 hours. Within each job, MCMC was implemented using the R2jags software
package (Su and Yajima, 2015).
We then re-estimate each patient’s risk using IS, taking as input only the population-level parameter posteriors
from the MCMC step. When generating values for the patient-level variables bi, we further increase the diversity
of the proposal set by we drawing 10 values from g(bi|θ(j)) for each posterior draw θ(j), for a total of 5 million
proposals. We experimented with approaches of using only 50,000 proposals, using all 5 million proposals, or
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starting with 50,000 and increasing number of proposals until the effective sample size exceeds 1000. We refer to
the first two approaches as “fixed” methods and the last approach as “dynamic”. Within each approach, the final
set of proposals were then weighted to obtain IS risk estimates. These simulation steps are meant to approximate
the procedure of using IS to get risk estimates for a new patient, under the assumption that any individual patient
has only a minor affect on the population-level parameter posteriors. In section 4.1, we assess coherence between
IS risk estimates and MCMC risk estimates.
4.1 Results
We find a high degree of coherence between the estimated posterior probability of aggressive cancer from IS
and from MCMC, as shown in Figure 1. With the dynamic proposal approach, the root mean square of the
difference (rMSD) between these two sets of risk estimates was 1.3% (on the probability scale, from 0% to 100%).
The maximum absolute difference was 5.9%, with 99% of patients having a difference less than 4.5%. Of the
approaches using a fixed number of proposals, the corresponding maximum and 99% quantile of differences were
16.6% and 5.6% for 50,000 proposals and 4.8% and 3.5% for 5 million proposal. We also considered a rejection
sampling approach using the unstandardized weights in Eq 3 but found the results to have a greater deviation
from MCMC estimates (rMSD = 1.6% for the dynamic approach).
Figure 3 illustrates the roughly inverse relationship between the effective sample size used for IS and the
difference between IS and MCMC risk estimates.3 Here, all three approaches performed similarly, with the fixed
50,000-proposal approach being the fastest. Computation time per patient ranged from 1.5-13.5 minutes, 1.4
seconds - 5.9 minutes, and 1.4-2.8 seconds for the 5-million-proposal, dynamic, and 50,000-proposal approaches,
respectively. Interquartile ranges for the per-patient calculation times of three methods were 3.1-3.9 minutes,
2.3-4.6 seconds, and 2.3-2.5 seconds.
These findings suggest that the proposed IS algorithm can be an appropriate substitute for full MCMC runs
in order to provide real-time updates in a clinical setting.
5 Discussion
The joint model of Coley et al. (2015) is among a growing number of statistical models for making individu-
alized health predictions and recommendations. Development of such precision medicine methods must occur
within a framework for clinical implementation. Specifically, concerns about convenience, security, and effective
communication must be addressed alongside statistical considerations. In this technical report, we present a fast
implementation of the of latent health state model proposed in Coley et al. (2015), using importance sampling to
generate in-clinic predictions. This approach informs decision-making by enabling doctors and patients to access
updated predictions in real-time in a clinical setting.
Supplemental Code
Code for simulating data, obtaining IS estimates, and comparing the results against MCMC estimates is available
at: https://github.com/aaronjfisher/in-clinic-updates-PSA
3It is worth noting, however, that the differences did not tend to decrease at a rate proportional to the square root of the effective
sample size.
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Figure 1: Agreement between IS and MCMC estimates for the posterior predictions of aggressive prostate cancer
state in a new patient. Point color represents the number of candidate points used – 50,000, 5 million, or dynamic.
The dashed line indicates the axis of equality (i.e., perfect agreement).
Figure 2: Difference between IS and MCMC risk estimates as a function of effective sample size for IS. Point color
represents the number of candidate points used – 50,000, 5 million, or dynamic. The dotted vertical line shows
the threshold used for dynamic proposal generation at an effective sample size of 1,000. Both axes are shown
with log-scale spacing.
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